Validation of the Effectiveness and Safety of Temozolomide during and after Radiotherapy for Newly Diagnosed Glioblastomas: 10-year Experience of a Single Institution
Open Access
- 1 January 2015
- journal article
- research article
- Published by XMLink in Journal of Korean Medical Science
- Vol. 30 (11) , 1597-1603
Abstract
Joo JD, et al. J Korean Med Sci. 2015 Nov;30(11):1597-1603. http://dx.doi.org/10.3346/jkms.2015.30.11.1597Keywords
This publication has 23 references indexed in Scilit:
- Temozolomide during and after Radiotherapy for Newly Diagnosed Glioblastomas : A Prospective Multicenter Study of Korean PatientsJournal of Korean Neurosurgical Society, 2012
- High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2010
- Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastomaNeuro-Oncology, 2010
- Epidemiology of Brain Tumors2009
- The Outcomes of Concomitant Chemoradiotherapy Followed by Adjuvant Chemotherapy with Temozolomide for Newly Diagnosed High Grade Gliomas : The Preliminary Results of Single Center Prospective StudyJournal of Korean Neurosurgical Society, 2008
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005
- Temozolomide as First-Line Agent in Treating High-Grade Gliomas: Phase II StudyJournal of Neuro-Oncology, 2004
- Factors influencing survival in high-grade gliomasSeminars in Oncology, 2003
- Brain TumorsNew England Journal of Medicine, 2001
- Response criteria for phase II studies of supratentorial malignant glioma.Journal of Clinical Oncology, 1990